In the present study, estimation of the completeness of cancer registry data using the two-source capture-recapture method and Petersen-Chapman model indicated the underestimation rate to be 45.8% during a three-year period. According to the literature, stomach cancer is the most life-threatening type of cancer in Iran, and underestimation rate for this cancer was 32.4%. The sensitivity of cancer registry systems was lower for women compared to men in this regard which was consistent with other research (
21). Despite the low coverage, cancer registry increased by 15.5% for all cancers from 2008 to 2010 year; however, this rate might vary in previous studies depending on different regions of the country. For instance, in a previous study, cancer registry coverage based on pathology registry during 2000 - 2007, as well as population-based and pathology registries during 2007-2009, varied from 22.68% to 118.7% (
6). In another study conducted in northwestern Iran using the capture-recapture method, under-ascertainment rate for all cancers during 2008 - 2010 was 16.1%, and coverage of the Iranian population-based registry was 52%, while it was 93.1% according to both data sources. In the mentioned study, the underestimation rate was 6.9% (
22). Furthermore, overall estimation of cancer registry coverage using the three-source capture-recapture method during 2008 - 2010 was 51%, and it ranged from 46.8% to 85.3% for stomach cancer (
23).
In the current study, cancer registry coverage was observed to increase with the age of patients, with the highest and lowest coverage reported within the age groups of 60 years or above and less than 40 years, respectively. This finding is consistent with the results of the studies conducted in Iran and Japan in this regard (
23,
24).
During 1990 - 2009, cancer registry coverage based on pathology registry, clinical records and cancer deaths in Gambia was reported to be 50.4% using the capture-recapture method (
25). Although cancer registry coverage may vary depending on the cancer type, coverage improvement in some regions of Iran could be attributed to the effective communication with reporting centers, such as laboratories and clinical or pathological centers.
In comparison with the indicators measuring the quality of cancer registry data in European countries, where coverage completeness is 96% - 100% (
26), cancer registry coverage is relatively low in our country. One of the indicators to evaluate the quality of cancer registry involves the verification of the status of childhood cancers due to the stable incidence in this patient population (
19). In 2010, childhood cancers and cancers in persons more than 80 years of age were accounted for 1.5% and 11% of the total number of cases, respectively, which almost corresponded with the international standards. However, the age-specific incidence rate of cancer in girls aged 5 - 9 years and boys aged 10 - 14 years was lower than the minimum of the recommended international standards, while these values were above the standard range in developed countries, such as Norway (
26). Low age-specific rate of cancer in these patient groups could be due to factors such as underestimation and lack of registration, report from pediatric hospitals and attention of healthcare authorities to this issue. The incidence-to-mortality ratio of cancer was 67%, while it is 80% based on the international standards (
19). As such, it could be concluded that cancer mortality rate in our country is 13% higher than the international standards (mortality-to-incidence ratio of cancer in our study was 33.7% for men and 28.2% for women).
Evaluation of cancer registry data in Golestan province in 2007 indicated that the mortality-to-incidence ratio for male and female patients was 47.6% and 35.8%, respectively (
20). In Japan, this ratio was 47% and 44% for men and women, and was 48.4% and 55.9% for male and female in northern Portugal, respectively (
24). In China in 2010, overall mortality-to-incidence ratio of cancer was 61%, which is consistent with the results of the present study (
27). Differences in this index in various countries could be due to the difficultly in the collection of data on cancer mortality, high case fatality rate, high rate of death registration, late diagnosis of cancer, and ineffective care of cancer patients. However, the exact causes of these differences are not distinguishable. For instance, in countries such as Finland, where the quality of data registry is relatively high, differences in the aforementioned ratios are insignificant, which could be attributed to factors such as the high rate of survival among cancer patients, effective screening programs, and accurate diagnosis and treatment of cancer. It is also noteworthy that these ratios may vary as much as 20% depending on the geographical region, age group of patients, and type of cancer (
19). Use of this index requires high-quality death registration data and accurate registry of the cause of death (
28). In the current study, percentage of cancer registry data through DCO was higher compared to the international standards. In the population-based cancer registry of the ministry of health and medical education in 2005, this index was reported to be 2% and 37.3% in Isfahan and Lorestan provinces, respectively. In another study, pathology registry during 1998 - 2001 indicated the number of cancer registries in terms of DCO to be 24% (
29), while this value was 9.9% for men and 7.3% for women in Golestan province (
20).
Rate of cancer registries based on DCO was reported to be respectively 2% and 1.7% for men and women in Antalya, while it was 4.4% and 3.9% in Izmir, 1.5% and 1.3% in Singapore, 2.9% and 3.2% in New Zealand, and 0.2% in Iceland, all of which were lower than the international standards. On the other hand, in countries such as Zimbabwe, this rate was reported to be respectively 13.3% and 9.7% for men and women, and 13.1% and 13.3% in Osaka (Japan) (
27). In a study performed in this regard in Norway in 2009, DCO for all cancers was 0.9% (
26). In addition, in a study of 25 population-based cancer registries in Japan in 2008, DCO was estimated at 13.2% and 14.1% for men and women, respectively (
24).
High number of registries based on DCO is suggestive of deficient coverage; as such, these cases should be interpreted in regional terms. In some developing countries, quality of death certificates may be very low or death certificates might be issued erroneously for other cases as cancer. In such cases, tracking hospital records by registries to prove or disprove death certificates in hospitals could be problematic. Data linkage methods in cancer registries should be applied to successfully detect the death certificates that already exist or are missing in the database. Except for DCOs where cancer is listed inaccurately as the cause of death, DCO represents the deficient identification of incident cancer cases. High percentage of DCO in Iran may be due to the underestimation by other sources, incomplete follow-up of patients or both these factors.
In the current study, we investigated the cancer data during 2008 - 2010, and found that the high percentage of DCO could be due to the fact that the obtained death files were not linked to cancer registry the period before the study. Typical sites for DCO are lung, liver and pancreas (
19), which are mostly of the metastatic type, the majority of DCO cases in both sexes were of lung and liver cancer (20.4% in women and 26.8% in men). To evaluate the percentage of morphological verification, this index was compared with the data of 17 countries from the Cancer incidence in five continents VOL.X; in this comparison our country was ranked 15, which is indicative of the low quality of morphological verification in Iran (
Figure 2). However, according to the cancer registry in Golestan province, the rate of morphologically verified cancer was estimated at 69.5% in men and 71.2% in women (
28). Moreover, the reported rates in Japan were 76% and 74.9% among men and women, respectively; these findings were consistent with the results of the present study (
24).
Comparison of Percentage of Morphologically Verified (MV%) Cancer Diagnoses in Iran and Selected Countries (2003 - 2007) for all Cancer Sites Combined in Terms of Sex (21)
Low percentage of morphological verification in the current study could be due to the underreporting of some pathology laboratories and centers, as well as the fact that a significant number of cancers are diagnosed at the time of death.
Out of 11,873 cases reported in 2010, the primary site of 593 cases (5%) was unknown, this could be due to metastases, or the fact that primary site was not determined or the provided reports lacked adequate information as to verify the primary site of tumors. As expected, incidence of tumors of unknown primary site was higher in elder patients, which corresponds with the international standards in this regard. According to international standards, the percentage of morphologically diagnosed cases was estimated at 80%, while DOC% ranged between 1% and 5%. Also, in 5% of cases, the site of tumor remained unspecified; other reported cases were found to be clinical (
19). In the current study, the highest age-specific rate was observed in cancer patients aged 80 - 84 years, and this rate dropped in older age groups. This reduction could be due to the lack of patient referral to cancer diagnosis centers, lack of access to diagnostic facilities and failure to perform diagnostic tests by physicians in this age group.
4.1. Limitations
There was some kind of limitation regarding this study: The cancer registry data was unavailable for the period before 2008 in chosen provinces due to lack of Health Information System in some of hospitals, so we could not match DCOs of 2008 with prior years. Furthermore, in some cases, cancer recorded as the cause of death while the patient maybe died for another reason which there was no possibility to track back follow the cause of death.
4.2. Conclusion
According to the results of this study, the quality of cancer registry data is relatively low in terms of the completeness and validity in our country. To increase coverage, cancer registry programs should be implemented in the national healthcare system, based on information obtained from various sources, including the laboratories, physicians’ offices, medical records, hospital information systems and death registries and other simple places. In this regard, quality of data should be assessed systematically in order to achieve the gold standards. Therefore, it is recommended that healthcare authorities implement the required interventions so as to prevent unnecessary costs associated with the collection of low-quality cancer registry data.